![ELCC2024_Audience_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_audience_01/18940309-1-eng-GB/elcc2024_audience_01_i770.jpg)
Promising efficacy data reported for a targeted agent harbouring a MET alteration in NSCLC
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different